Listed

Immunovant, Inc.

IMVTNasdaqCIK 1764013HealthcareFiscal year ends Mar 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Net income−$153.2m, Q1 FY2027
Immunovant, Inc., income statement, quarterly
Line itemUnitQ2 FY20242023-09-30Q3 FY20242023-12-31Q4 FY20242024-03-31Q1 FY20252024-06-30Q2 FY20252024-09-30Q3 FY20252024-12-31Q4 FY20252025-03-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31Q4 FY20262026-03-31Q1 FY20272026-06-30
Research and development$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.5Income tax, Q2 FY2024, three months to 2023-09-30$454.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-07, accession 0001764013-24-000184.Report this figure(0.1)Income tax, Q3 FY2024, three months to 2023-12-31−$108.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure0.2Income tax, Q4 FY2024, three months to 2024-03-31$232.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2025, three months to 2024-06-30$77.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure0.1Income tax, Q2 FY2025, three months to 2024-09-30$78.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure0.2Income tax, Q3 FY2025, three months to 2024-12-31$152.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure0.6Income tax, Q4 FY2025, three months to 2025-03-31$583.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure0.9Income tax, Q1 FY2026, three months to 2025-06-30$913.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure0.6Income tax, Q2 FY2026, three months to 2025-09-30$594.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure1.6Income tax, Q3 FY2026, three months to 2025-12-31$1.6m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure(2.8)Income tax, Q4 FY2026, three months to 2026-03-31−$2.8m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2027, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure
Net income$m(58.7)Net income, Q2 FY2024, three months to 2023-09-30−$58.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure(51.4)Net income, Q3 FY2024, three months to 2023-12-31−$51.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure(75.3)Net income, Q4 FY2024, three months to 2024-03-31−$75.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure(87.2)Net income, Q1 FY2025, three months to 2024-06-30−$87.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure(109)Net income, Q2 FY2025, three months to 2024-09-30−$109.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure(111)Net income, Q3 FY2025, three months to 2024-12-31−$111.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure(106)Net income, Q4 FY2025, three months to 2025-03-31−$106.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure(121)Net income, Q1 FY2026, three months to 2025-06-30−$120.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure(127)Net income, Q2 FY2026, three months to 2025-09-30−$126.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure(111)Net income, Q3 FY2026, three months to 2025-12-31−$110.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure(148)Net income, Q4 FY2026, three months to 2026-03-31−$147.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure(153)Net income, Q1 FY2027, three months to 2026-06-30−$153.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure
Diluted EPS$ per share(0.45)Diluted EPS, Q2 FY2024, three months to 2023-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0001764013-24-000184.Report this figure(0.36)Diluted EPS, Q3 FY2024, three months to 2023-12-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figurenot reported(0.60)Diluted EPS, Q1 FY2025, three months to 2024-06-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure(0.74)Diluted EPS, Q2 FY2025, three months to 2024-09-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure(0.76)Diluted EPS, Q3 FY2025, three months to 2024-12-31−$0.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figurenot reported(0.71)Diluted EPS, Q1 FY2026, three months to 2025-06-30−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure(0.73)Diluted EPS, Q2 FY2026, three months to 2025-09-30−$0.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure(0.61)Diluted EPS, Q3 FY2026, three months to 2025-12-31−$0.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figurenot reported(0.75)Diluted EPS, Q1 FY2027, three months to 2026-06-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure
Basic EPS$ per share(0.45)Basic EPS, Q2 FY2024, three months to 2023-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0001764013-24-000184.Report this figure(0.36)Basic EPS, Q3 FY2024, three months to 2023-12-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figurenot reported(0.60)Basic EPS, Q1 FY2025, three months to 2024-06-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure(0.74)Basic EPS, Q2 FY2025, three months to 2024-09-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure(0.76)Basic EPS, Q3 FY2025, three months to 2024-12-31−$0.76 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figurenot reported(0.71)Basic EPS, Q1 FY2026, three months to 2025-06-30−$0.71 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure(0.73)Basic EPS, Q2 FY2026, three months to 2025-09-30−$0.73 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure(0.61)Basic EPS, Q3 FY2026, three months to 2025-12-31−$0.61 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figurenot reported(0.75)Basic EPS, Q1 FY2027, three months to 2026-06-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure

Balance sheet

Cash and equivalents$797.8m, Q1 FY2027
Shareholders' equity$735.4m, Q1 FY2027
Immunovant, Inc., balance sheet, quarterly
Line itemUnitQ2 FY20242023-09-30Q3 FY20242023-12-31FY20242024-03-31Q1 FY20252024-06-30Q2 FY20252024-09-30Q3 FY20252024-12-31FY20252025-03-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31FY20262026-03-31Q1 FY20272026-06-30
Cash and equivalents$m270Cash and equivalents, Q2 FY2024, at 2023-09-30$269.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001764013-23-000133.Report this figure691Cash and equivalents, Q3 FY2024, at 2023-12-31$690.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-02-12, accession 0001764013-24-000026.Report this figure635Cash and equivalents, FY2024, at 2024-03-31$635.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-05-29, accession 0001764013-25-000092.Report this figure560Cash and equivalents, Q1 FY2025, at 2024-06-30$560.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-06, accession 0001764013-24-000148.Report this figure473Cash and equivalents, Q2 FY2025, at 2024-09-30$472.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001764013-24-000184.Report this figure375Cash and equivalents, Q3 FY2025, at 2024-12-31$374.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure714Cash and equivalents, FY2025, at 2025-03-31$714.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-05-20, accession 0001764013-26-000064.Report this figure599Cash and equivalents, Q1 FY2026, at 2025-06-30$598.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure522Cash and equivalents, Q2 FY2026, at 2025-09-30$521.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure995Cash and equivalents, Q3 FY2026, at 2025-12-31$994.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure902Cash and equivalents, FY2026, at 2026-03-31$902.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure798Cash and equivalents, Q1 FY2027, at 2026-06-30$797.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure
Current assets$m291Current assets, Q2 FY2024, at 2023-09-30$291.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001764013-23-000133.Report this figure711Current assets, Q3 FY2024, at 2023-12-31$710.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-02-12, accession 0001764013-24-000026.Report this figure666Current assets, FY2024, at 2024-03-31$665.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-05-29, accession 0001764013-25-000092.Report this figure589Current assets, Q1 FY2025, at 2024-06-30$589.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0001764013-24-000148.Report this figure507Current assets, Q2 FY2025, at 2024-09-30$507.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0001764013-24-000184.Report this figure413Current assets, Q3 FY2025, at 2024-12-31$412.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure768Current assets, FY2025, at 2025-03-31$767.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-05-20, accession 0001764013-26-000064.Report this figure652Current assets, Q1 FY2026, at 2025-06-30$651.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure574Current assets, Q2 FY2026, at 2025-09-30$573.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure1,043Current assets, Q3 FY2026, at 2025-12-31$1.04bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure949Current assets, FY2026, at 2026-03-31$948.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure851Current assets, Q1 FY2027, at 2026-06-30$851.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure
Total assets$m292Total assets, Q2 FY2024, at 2023-09-30$292.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001764013-23-000133.Report this figure711Total assets, Q3 FY2024, at 2023-12-31$711.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-02-12, accession 0001764013-24-000026.Report this figure666Total assets, FY2024, at 2024-03-31$666.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-05-29, accession 0001764013-25-000092.Report this figure590Total assets, Q1 FY2025, at 2024-06-30$589.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0001764013-24-000148.Report this figure516Total assets, Q2 FY2025, at 2024-09-30$515.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0001764013-24-000184.Report this figure421Total assets, Q3 FY2025, at 2024-12-31$420.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure776Total assets, FY2025, at 2025-03-31$776.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-05-20, accession 0001764013-26-000064.Report this figure661Total assets, Q1 FY2026, at 2025-06-30$661.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure583Total assets, Q2 FY2026, at 2025-09-30$583.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure1,052Total assets, Q3 FY2026, at 2025-12-31$1.05bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure957Total assets, FY2026, at 2026-03-31$957.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure852Total assets, Q1 FY2027, at 2026-06-30$852.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure
Current liabilities$m40.3Current liabilities, Q2 FY2024, at 2023-09-30$40.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001764013-23-000133.Report this figure32.1Current liabilities, Q3 FY2024, at 2023-12-31$32.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-02-12, accession 0001764013-24-000026.Report this figure48.6Current liabilities, FY2024, at 2024-03-31$48.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-05-29, accession 0001764013-25-000092.Report this figure45.0Current liabilities, Q1 FY2025, at 2024-06-30$45.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0001764013-24-000148.Report this figure66.7Current liabilities, Q2 FY2025, at 2024-09-30$66.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0001764013-24-000184.Report this figure68.3Current liabilities, Q3 FY2025, at 2024-12-31$68.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure68.8Current liabilities, FY2025, at 2025-03-31$68.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-05-20, accession 0001764013-26-000064.Report this figure52.9Current liabilities, Q1 FY2026, at 2025-06-30$52.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure63.3Current liabilities, Q2 FY2026, at 2025-09-30$63.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure66.3Current liabilities, Q3 FY2026, at 2025-12-31$66.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure104Current liabilities, FY2026, at 2026-03-31$104.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure117Current liabilities, Q1 FY2027, at 2026-06-30$117.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure
Total liabilities$m40.3Total liabilities, Q2 FY2024, at 2023-09-30$40.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001764013-23-000133.Report this figure32.1Total liabilities, Q3 FY2024, at 2023-12-31$32.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-02-12, accession 0001764013-24-000026.Report this figure48.6Total liabilities, FY2024, at 2024-03-31$48.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-05-29, accession 0001764013-25-000092.Report this figure45.0Total liabilities, Q1 FY2025, at 2024-06-30$45.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0001764013-24-000148.Report this figure66.7Total liabilities, Q2 FY2025, at 2024-09-30$66.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0001764013-24-000184.Report this figure68.3Total liabilities, Q3 FY2025, at 2024-12-31$68.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure68.8Total liabilities, FY2025, at 2025-03-31$68.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-05-20, accession 0001764013-26-000064.Report this figure52.9Total liabilities, Q1 FY2026, at 2025-06-30$52.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure63.3Total liabilities, Q2 FY2026, at 2025-09-30$63.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure66.3Total liabilities, Q3 FY2026, at 2025-12-31$66.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure104Total liabilities, FY2026, at 2026-03-31$104.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure117Total liabilities, Q1 FY2027, at 2026-06-30$117.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure
Shareholders' equity$m252Shareholders' equity, Q2 FY2024, at 2023-09-30$251.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure679Shareholders' equity, Q3 FY2024, at 2023-12-31$679.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure618Shareholders' equity, FY2024, at 2024-03-31$617.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-05-20, accession 0001764013-26-000064.Report this figure545Shareholders' equity, Q1 FY2025, at 2024-06-30$544.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure449Shareholders' equity, Q2 FY2025, at 2024-09-30$449.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure353Shareholders' equity, Q3 FY2025, at 2024-12-31$352.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure707Shareholders' equity, FY2025, at 2025-03-31$707.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure609Shareholders' equity, Q1 FY2026, at 2025-06-30$608.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure520Shareholders' equity, Q2 FY2026, at 2025-09-30$519.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure986Shareholders' equity, Q3 FY2026, at 2025-12-31$986.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure853Shareholders' equity, FY2026, at 2026-03-31$852.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure735Shareholders' equity, Q1 FY2027, at 2026-06-30$735.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure

Cash flow

Operating cash flow−$124.4m, Q1 FY2027
Capital expenditure$8.0k, Q4 FY2026
Immunovant, Inc., cash flow, quarterly
Line itemUnitQ2 FY20242023-09-30Q3 FY20242023-12-31Q4 FY20242024-03-31Q1 FY20252024-06-30Q2 FY20252024-09-30Q3 FY20252024-12-31Q4 FY20252025-03-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31Q4 FY20262026-03-31Q1 FY20272026-06-30
Operating cash flow$m(60.1)Operating cash flow, Q2 FY2024, three months to 2023-09-30−$60.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0001764013-24-000184. Derived: 6-month figure less the 3-month figure.Report this figure(47.1)Operating cash flow, Q3 FY2024, three months to 2023-12-31−$47.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-02-06, accession 0001764013-25-000026. Derived: 9-month figure less the 6-month figure.Report this figure(59.7)Operating cash flow, Q4 FY2024, three months to 2024-03-31−$59.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure(76.2)Operating cash flow, Q1 FY2025, three months to 2024-06-30−$76.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure(88.6)Operating cash flow, Q2 FY2025, three months to 2024-09-30−$88.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001764013-25-000149. Derived: 6-month figure less the 3-month figure.Report this figure(100)Operating cash flow, Q3 FY2025, three months to 2024-12-31−$100.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-06, accession 0001764013-26-000011. Derived: 9-month figure less the 6-month figure.Report this figure(111)Operating cash flow, Q4 FY2025, three months to 2025-03-31−$110.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure(117)Operating cash flow, Q1 FY2026, three months to 2025-06-30−$117.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure(103)Operating cash flow, Q2 FY2026, three months to 2025-09-30−$102.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001764013-25-000149. Derived: 6-month figure less the 3-month figure.Report this figure(92.3)Operating cash flow, Q3 FY2026, three months to 2025-12-31−$92.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-06, accession 0001764013-26-000011. Derived: 9-month figure less the 6-month figure.Report this figure(95.1)Operating cash flow, Q4 FY2026, three months to 2026-03-31−$95.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure(124)Operating cash flow, Q1 FY2027, three months to 2026-06-30−$124.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure
Capital expenditure$m0.0Capital expenditure, Q2 FY2024, three months to 2023-09-30$34.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0001764013-24-000184. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2023-12-31$131.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-02-06, accession 0001764013-25-000026. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2024, three months to 2024-03-31$150.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2025, three months to 2024-06-30$182.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2024-09-30$196.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001764013-25-000149. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2025, three months to 2024-12-31$180.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-06, accession 0001764013-26-000011. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2025, three months to 2025-03-31$201.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001764013-25-000149. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2026, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-06, accession 0001764013-26-000011. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2026, three months to 2026-03-31$8.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-05-20, accession 0001764013-26-000064. Derived: 12-month figure less the 9-month figure.Report this figurenot reported

Shares

Diluted shares (weighted)205.55m, Q1 FY2027
Immunovant, Inc., shares, quarterly
Line itemUnitQ2 FY20232022-09-30Q3 FY20232022-12-31Q1 FY20242023-06-30Q2 FY20242023-09-30Q3 FY20242023-12-31Q1 FY20252024-06-30Q2 FY20252024-09-30Q3 FY20252024-12-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31Q1 FY20272026-06-30
Diluted shares (weighted)m shares117Diluted shares (weighted), Q2 FY2023, three months to 2022-09-30116,572,820 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001764013-23-000133.Report this figure129Diluted shares (weighted), Q3 FY2023, three months to 2022-12-31128,574,190 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-02-12, accession 0001764013-24-000026.Report this figure131Diluted shares (weighted), Q1 FY2024, three months to 2023-06-30130,503,264 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0001764013-24-000148.Report this figure131Diluted shares (weighted), Q2 FY2024, three months to 2023-09-30131,155,642 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0001764013-24-000184.Report this figure145Diluted shares (weighted), Q3 FY2024, three months to 2023-12-31144,523,034 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-02-06, accession 0001764013-25-000026.Report this figure146Diluted shares (weighted), Q1 FY2025, three months to 2024-06-30146,085,729 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001764013-25-000129.Report this figure146Diluted shares (weighted), Q2 FY2025, three months to 2024-09-30146,468,991 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure147Diluted shares (weighted), Q3 FY2025, three months to 2024-12-31146,922,338 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure171Diluted shares (weighted), Q1 FY2026, three months to 2025-06-30170,872,994 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure174Diluted shares (weighted), Q2 FY2026, three months to 2025-09-30173,643,829 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001764013-25-000149.Report this figure182Diluted shares (weighted), Q3 FY2026, three months to 2025-12-31181,513,386 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-02-06, accession 0001764013-26-000011.Report this figure206Diluted shares (weighted), Q1 FY2027, three months to 2026-06-30205,545,373 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure

Shares outstanding: 206.55mShares outstanding, period not labelled, at 2026-08-03206,552,682 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001764013-26-000101.Report this figure at Aug 3, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.